Bloomage Biotechnology Corp Ltd (688363) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bloomage Biotechnology Corp Ltd (688363) has a cash flow conversion efficiency ratio of 0.013x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥93.75 Million ≈ $13.72 Million USD) by net assets (CN¥7.09 Billion ≈ $1.04 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Bloomage Biotechnology Corp Ltd defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Bloomage Biotechnology Corp Ltd - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Bloomage Biotechnology Corp Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Bloomage Biotechnology Corp Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bloomage Biotechnology Corp Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sunway Construction Group Bhd
KLSE:5263
|
-0.090x |
|
Olin Corporation
NYSE:OLN
|
0.160x |
|
Chongqing Zaisheng Tech Corp
SHG:603601
|
0.066x |
|
Bird Construction Inc.
TO:BDT
|
0.014x |
|
Chicony Electronics Co Ltd
TW:2385
|
0.036x |
|
AstraZeneca PLC
LSE:AZN
|
0.071x |
|
Fuchs Petrolub SE
XETRA:FPE
|
0.034x |
|
IGB Real Estate Investment Trust
KLSE:5227
|
0.016x |
Annual Cash Flow Conversion Efficiency for Bloomage Biotechnology Corp Ltd (2012–2025)
The table below shows the annual cash flow conversion efficiency of Bloomage Biotechnology Corp Ltd from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see 688363 company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥7.12 Billion ≈ $1.04 Billion |
CN¥627.45 Million ≈ $91.82 Million |
0.088x | +6.85% |
| 2024-12-31 | CN¥6.84 Billion ≈ $1.00 Billion |
CN¥564.51 Million ≈ $82.60 Million |
0.083x | -17.62% |
| 2023-12-31 | CN¥6.98 Billion ≈ $1.02 Billion |
CN¥699.65 Million ≈ $102.38 Million |
0.100x | +5.41% |
| 2022-12-31 | CN¥6.68 Billion ≈ $977.93 Million |
CN¥635.19 Million ≈ $92.95 Million |
0.095x | -57.53% |
| 2021-12-31 | CN¥5.70 Billion ≈ $834.45 Million |
CN¥1.28 Billion ≈ $186.73 Million |
0.224x | +61.67% |
| 2020-12-31 | CN¥5.09 Billion ≈ $745.44 Million |
CN¥705.12 Million ≈ $103.18 Million |
0.138x | +72.58% |
| 2019-12-31 | CN¥4.55 Billion ≈ $665.74 Million |
CN¥364.89 Million ≈ $53.40 Million |
0.080x | -68.86% |
| 2018-12-31 | CN¥1.72 Billion ≈ $251.32 Million |
CN¥442.30 Million ≈ $64.72 Million |
0.258x | +22.81% |
| 2017-12-31 | CN¥1.64 Billion ≈ $239.65 Million |
CN¥343.42 Million ≈ $50.25 Million |
0.210x | +9.39% |
| 2016-12-31 | CN¥1.26 Billion ≈ $184.47 Million |
CN¥241.68 Million ≈ $35.36 Million |
0.192x | +56.87% |
| 2015-12-31 | CN¥1.19 Billion ≈ $174.42 Million |
CN¥145.67 Million ≈ $21.32 Million |
0.122x | -33.10% |
| 2014-12-31 | CN¥752.51 Million ≈ $110.12 Million |
CN¥137.47 Million ≈ $20.12 Million |
0.183x | -33.62% |
| 2013-12-31 | CN¥564.35 Million ≈ $82.58 Million |
CN¥155.33 Million ≈ $22.73 Million |
0.275x | +24.08% |
| 2012-12-31 | CN¥376.97 Million ≈ $55.16 Million |
CN¥83.62 Million ≈ $12.24 Million |
0.222x | -- |
About Bloomage Biotechnology Corp Ltd
Bloomage BioTechnology Corporation Limited researchers, develops, produces, and sells bioactive materials. It offers pharmaceutical grade sodium hyaluronate which can be used as an API or excipient for drugs and medical devices in ophthalmic preparations, intra-articular injections, anti-adhesive preparations, and topical preparations for wound healing and soft tissue filler under the Hyature nam… Read more